Advertisement
Advertisement
U.S. markets close in 1 hour 49 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Adicet Bio, Inc. (ACET)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
10.42+0.24 (+2.36%)
As of 02:06PM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close10.18
Open10.08
Bid10.35 x 900
Ask10.45 x 900
Day's Range9.77 - 10.70
52 Week Range6.25 - 17.80
Volume216,113
Avg. Volume102,235
Market Cap332.975M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.01
Earnings DateNov 10, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ACET

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Adicet Bio, Inc.
    ACIW: Lowering target price to $34.00ACI WORLDWIDE INC has an Investment Rating of HOLD; a target price of $34.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of High.
    Rating
    Fair Value
    Economic Moat
    8 days agoArgus Research
View more
  • GlobeNewswire

    Adicet Bio to Host Webcast Presentation of ADI-001 Interim Clinical Data in B Cell Non-Hodgkin’s Lymphoma

    ADI-001 is the first ever allogeneic, off-the-shelf, gamma delta CAR T cell therapy to report clinical data Event to be webcast on December 6, 2021 at 8:30 a.m. EST MENLO PARK, Calif. and BOSTON, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that the Company will host a webcast presentation on Monday, December 6, 2021 at 8:3

  • Simply Wall St.

    Adicet Bio (NASDAQ:ACET) shareholders have endured a 27% loss from investing in the stock a year ago

    It is doubtless a positive to see that the Adicet Bio, Inc. ( NASDAQ:ACET ) share price has gained some 35% in the last...

  • GlobeNewswire

    Adicet Announces Appointment of Dr. Michael G. Kauffman to the Board of Directors

    MENLO PARK, Calif. and BOSTON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the appointment of Michael G. Kauffman, M.D., Ph.D., to its Board of Directors. "Dr. Kauffman’s appointment brings a wealth of expertise to our board and will be invaluable as we advance the development of our pipeline of next-generation off-the-she

Advertisement
Advertisement